[1]Patent:WO2010/61400,2010,A1.Locationinpatent:Page/Pagecolumn17
[2]Patent:US2011/263852,2011,A1.Locationinpatent:Page/Pagecolumn12
[3]Patent:WO2006/26313,2006,A2.Locationinpatent:Page/Pagecolumn24-25
[4]Patent:CN105503839,2016,A.Locationinpatent:Paragraph0046;0049;0050
[5]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn24
[6]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn25
[7]Patent:CN106432205,2017,A.Locationinpatent:Paragraph0052;0053;0054
[8]Patent:US2009/281315,2009,A1.Locationinpatent:Page/Pagecolumn9
[9]Patent:WO2005/46678,2005,A1.Locationinpatent:Page/Pagecolumn69-70
[10]Patent:WO2010/17387,2010,A2.Locationinpatent:Page/Pagecolumn30
[11]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn23;24
[12]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn25-26
[13]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn26-27
[14]Patent:WO2011/39759,2011,A1.Locationinpatent:Page/Pagecolumn16;17
[15]Patent:WO2011/116634,2011,A1.Locationinpatent:Page/Pagecolumn16-17
[16]Patent:WO2011/130831,2011,A1.Locationinpatent:Page/Pagecolumn15;16
[17]Patent:WO2012/17448,2012,A2.Locationinpatent:Page/Pagecolumn10-11
[18]Patent:US2015/65710,2015,A1.Locationinpatent:Page/Pagecolumn0123-0125
[19]Patent:WO2005/120512,2005,A2.Locationinpatent:Page/Pagecolumn25
[20]Patent:WO2005/120504,2005,A2.Locationinpatent:Page/Pagecolumn32
[21]Patent:WO2007/121279,2007,A2.Locationinpatent:Page/Pagecolumn42;45
[22]Patent:WO2005/105094,2005,A2.Locationinpatent:Page/Pagecolumn46-47
[1]Patent:WO2014/188226,2014,A2.Locationinpatent:Page/Pagecolumn47-48
[2]Patent:US2010/87459,2010,A1.Locationinpatent:Page/Pagecolumn7
[3]Patent:WO2009/79541,2009,A1.Locationinpatent:Page/Pagecolumn23
[4]Patent:WO2009/79547,2009,A1.Locationinpatent:Page/Pagecolumn18
[5]Patent:WO2011/116634,2011,A1.Locationinpatent:Page/Pagecolumn17
[6]CrystalGrowthandDesign,2016,vol.16,p.6122-6130
104-15-4
[1]CurrentPatentAssignee:HOLDINGF.I.S.S.P.A.-WO2015/162007,2015,A1Locationinpatent:Paragraph00117;00118;00119;0020;00121;00122
[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-US2010/87459,2010,A1Locationinpatent:Page/Pagecolumn7
[1]Patent:CN106432206,2017,A.Locationinpatent:Paragraph0034;0051;0052;0053
Title: P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2.
Journal: Chemical research in toxicology 20160516
Title: Better Together: Targeted Combination Therapies in Breast Cancer.
Journal: Seminars in oncology 20151201
Title: Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Journal: Toxicology and applied pharmacology 20150815
Title: Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
Journal: European journal of medicinal chemistry 20131101
Title: Lapatinib inhibits meiotic maturation of porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium.
Journal: Fertility and sterility 20130501
Title: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501
Title: Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Journal: Oncology reports 20121201
Title: Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Journal: Molecular pharmaceutics 20121105
Title: Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.
Journal: Nanotechnology 20121102
Title: Dual blockade of HER2 - twice as good or twice as toxic?
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20121101
Title: Targeted therapy in brain metastasis.
Journal: Current opinion in oncology 20121101
Title: Lapatinib and renal cell carcinoma.
Journal: Expert opinion on investigational drugs 20121101
Title: Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Journal: Gynecologic oncology 20121101
Title: Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care 20121001
Title: A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Journal: Investigational new drugs 20121001
Title: Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Journal: Molecular bioSystems 20121001
Title: Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Journal: Molecular oncology 20121001
Title: Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Journal: Breast cancer research and treatment 20121001
Title: Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Journal: British journal of cancer 20120925
Title: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120910
Title: BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Journal: British journal of cancer 20120904
Title: Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Journal: British journal of cancer 20120904
Title: Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.
Journal: Medical oncology (Northwood, London, England) 20120901
Title: T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Journal: The Journal of investigative dermatology 20120901
Title: Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Journal: Molecular cancer therapeutics 20120901
Title: Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Journal: Neuro-oncology 20120901
Title: Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120901
Title: Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Journal: Anticancer research 20120901
Title: A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Journal: Experimental & molecular medicine 20120831
Title: Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Journal: Fundamental & clinical pharmacology 20120801
Title: Docetaxel combined with targeted therapies in metastatic breast cancer.
Journal: Cancer treatment reviews 20120801
Title: Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Journal: Nanomedicine : nanotechnology, biology, and medicine 20120801
Title: New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Journal: Cancer treatment reviews 20120801
Title: Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Journal: Molecular oncology 20120801
Title: Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity.
Journal: Anesthesiology 20120801
Title: Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Journal: Current medical research and opinion 20120801
Title: Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
Journal: Anticancer research 20120801
Title: Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
Journal: The Lancet. Oncology 20120801
Title: Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Journal: Expert review of anticancer therapy 20120801
Title: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Journal: Nature 20120726
Title: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120720
Title: Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
Journal: Oncogene 20120719
Title: Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
Journal: JOP : Journal of the pancreas 20120710
Title: Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Journal: Breast cancer (Tokyo, Japan) 20120701
Title: Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Journal: International journal of cancer 20120701
Title: A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Journal: Breast cancer research and treatment 20120701
Title: Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Journal: Breast cancer research and treatment 20120701
Title: Interaction of lapatinib with cytochrome P450 3A5.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120701
Title: The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Journal: International journal of oncology 20120701
Title: Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Journal: Breast cancer research and treatment 20120701
Title: Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Journal: Breast cancer research and treatment 20120701
Title: [A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20120701
Title: New insights and emerging therapies for breast cancer brain metastases.
Journal: Oncology (Williston Park, N.Y.) 20120701
Title: Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
Journal: Drugs 20120618
Title: HER2 testing in patients with breast cancer.
Journal: BMJ (Clinical research ed.) 20120611
Title: The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120601
Title: Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120601
Title: Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.
Journal: Breast cancer research and treatment 20120601
Title: The adjuvant treatment of HER2-positive breast cancer.
Journal: Current treatment options in oncology 20120601
Title: Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
Journal: Oncology reports 20120601
Title: Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601
Title: [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
Journal: Bulletin du cancer 20120601
Title: Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Journal: Cell 20120511
Title: Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Journal: Oncology reports 20120501
Title: Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Journal: Molecular pharmacology 20120501
Title: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120501
Title: Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Journal: Cancer discovery 20120501
Title: A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120415
Title: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
Journal: Oncogene 20120405
Title: Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Journal: Investigational new drugs 20120401
Title: Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Journal: Breast cancer research and treatment 20120401
Title: Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Journal: Journal of cellular physiology 20120401
Title: Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120401
Title: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Journal: Gastroenterology 20120401
Title: Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
Journal: Molecular pharmacology 20120401
Title: Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.
Journal: Recent patents on DNA & gene sequences 20120401
Title: Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.
Journal: Clinical pharmacology and therapeutics 20120401
Title: HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Journal: Molecular cancer therapeutics 20120401
Title: Lapatinib for advanced or metastatic breast cancer.
Journal: The oncologist 20120401
Title: [Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].
Journal: Zhongguo shi yan xue ye xue za zhi 20120401
Title: A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
Journal: Biochemistry 20120327
Title: Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Journal: Journal of medicinal chemistry 20120322
Title: Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling.
Journal: Nature communications 20120313
Title: Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Journal: Pharmaceutical research 20120301
Title: A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Journal: Gynecologic oncology 20120301
Title: [Renal tolerance of targeted therapies].
Journal: Bulletin du cancer 20120301
Title: MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Journal: Molecular cancer therapeutics 20120301
Title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Journal: Lancet (London, England) 20120218
Title: Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Journal: British journal of cancer 20120214
Title: Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Journal: Cellular signalling 20120201
Title: The role of lapatinib in the preoperative therapy of breast cancer.
Journal: Current oncology reports 20120201
Title: Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Journal: Anti-cancer agents in medicinal chemistry 20120201
Title: Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Journal: Cancer science 20120201
Title: Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Journal: Breast cancer research and treatment 20120201
Title: Treatment of vestibular schwannoma cells with ErbB inhibitors.
Journal: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20120201
Title: Don't pick the loser: lessons from the GeparQuinto trial.
Journal: The Lancet. Oncology 20120201
Title: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Journal: The Lancet. Oncology 20120201
Title: Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Journal: Future oncology (London, England) 20120201
Title: Advances in medical therapies for Cushing's syndrome.
Journal: Discovery medicine 20120201
Title: In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Journal: Neoplasia (New York, N.Y.) 20120201
Title: Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20120101
Title: Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Journal: Breast cancer research and treatment 20120101
Title: Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120101
Title: Hepatotoxicity associated with lapatinib in an experimental rat model.
Journal: European journal of cancer (Oxford, England : 1990) 20120101
Title: Role of chemotherapy on brain metastasis.
Journal: Progress in neurological surgery 20120101
Title: Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
Journal: Journal of translational medicine 20120101
Title: What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?
Journal: Oncology (Williston Park, N.Y.) 20120101
Title: HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Journal: Oncology 20120101
Title: Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Journal: Tumori 20120101
Title: High lapatinib plasma levels in breast cancer patients: risk or benefit?
Journal: Tumori 20120101
Title: Die and let live: harnessing BikDD to combat breast cancer stem cells.
Journal: Breast cancer research : BCR 20120101
Title: Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
Journal: Molecular cancer 20120101
Title: Targeted therapies in breast cancer: are heart and vessels also being targeted?
Journal: Breast cancer research : BCR 20120101
Title: Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Journal: Oncology 20120101
Title: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Journal: BMC cancer 20120101
Title: Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Journal: PloS one 20120101
Title: The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Journal: Molecular systems biology 20120101
Title: Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Journal: PloS one 20120101
Title: hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111215
Title: Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
Journal: Investigational new drugs 20111201
Title: Modulation of P-gp expression by lapatinib.
Journal: Investigational new drugs 20111201
Title: Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Journal: International journal of clinical oncology 20111201
Title: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111201
Title: Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111201
Title: Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Journal: Cancer chemotherapy and pharmacology 20111201
Title: Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Journal: Journal of neuro-oncology 20111201
Title: Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Journal: Current medical research and opinion 20111201
Title: Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Journal: Nature structural & molecular biology 20111201
Title: Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
Journal: Oncology (Williston Park, N.Y.) 20111201
Title: Treatment of HER2-positive breast cancer: current status and future perspectives.
Journal: Nature reviews. Clinical oncology 20111129
Title: Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Journal: International journal of cancer 20111115
Title: An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Journal: British journal of cancer 20111108
Title: HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Journal: Breast cancer research and treatment 20111101
Title: Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Journal: Cancer 20111101
Title: Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Journal: Expert opinion on pharmacotherapy 20111101
Title: [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20111101
Title: Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Journal: Biochemical and biophysical research communications 20111014
Title: Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Journal: Investigational new drugs 20111001
Title: Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Journal: Breast (Edinburgh, Scotland) 20111001
Title: Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Journal: Breast (Edinburgh, Scotland) 20111001
Title: Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Journal: Oncogene 20110929
Title: Elucidating an uncommon disease: inflammatory breast cancer.
Journal: Journal of the National Cancer Institute 20110921
Title: An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Journal: Cancer discovery 20110915
Title: BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Journal: Cancer cell 20110913
Title: Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Journal: British journal of cancer 20110906
Title: Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.
Journal: Molecular cell 20110902
Title: Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model.
Journal: International journal of oncology 20110901
Title: Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20110901
Title: Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
Journal: Anticancer research 20110901
Title: Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Journal: Future cardiology 20110901
Title: Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Journal: British journal of cancer 20110823
Title: Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
Journal: Medical hypotheses 20110801
Title: Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Journal: Molecular cancer therapeutics 20110801
Title: Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Journal: Cancer prevention research (Philadelphia, Pa.) 20110801
Title: Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Journal: Molecular cancer therapeutics 20110801
Title: Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.
Journal: Cancer prevention research (Philadelphia, Pa.) 20110801
Title: Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110710
Title: Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.
Journal: Oncogene 20110707
Title: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
Journal: Breast cancer research and treatment 20110701
Title: Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Journal: Gynecologic oncology 20110701
Title: Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Journal: Current opinion in oncology 20110701
Title: ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.
Journal: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20110701
Title: Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?
Journal: Heart failure clinics 20110701
Title: Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.
Journal: Science translational medicine 20110608
Title: Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
Journal: Critical reviews in oncology/hematology 20110601
Title: The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110601
Title: Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110601
Title: A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.
Journal: Molecular bioSystems 20110601
Title: Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Journal: Clinical pharmacokinetics 20110601
Title: Cancer stem cells: perspectives of new therapeutical approaches for breast cancer.
Journal: Frontiers in bioscience (Scholar edition) 20110601
Title: [Tykerb for breast cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20110601
Title: Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Journal: Clinical advances in hematology & oncology : H&O 20110601
Title: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110515
Title: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Journal: Cancer research 20110515
Title: Lapatinib-induced hepatitis: a case report.
Journal: World journal of gastroenterology 20110514
Title: Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
Journal: Japanese journal of clinical oncology 20110501
Title: Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Journal: Chinese journal of cancer 20110501
Title: Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.
Journal: Drugs of today (Barcelona, Spain : 1998) 20110501
Title: HER2-targeted therapies: how far we've come--and where we're headed.
Journal: Oncology (Williston Park, N.Y.) 20110430
Title: Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Journal: Biochemical and biophysical research communications 20110408
Title: Hints of future progress for HER-2 breast cancer.
Journal: Journal of the National Cancer Institute 20110406
Title: Use of molecular markers for predicting therapy response in cancer patients.
Journal: Cancer treatment reviews 20110401
Title: Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Journal: Immunologic research 20110401
Title: Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Journal: Breast (Edinburgh, Scotland) 20110401
Title: A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.
Journal: Magma (New York, N.Y.) 20110401
Title: KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Journal: Oncology reports 20110401
Title: Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Journal: The Journal of biological chemistry 20110401
Title: Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Journal: Biochemical and biophysical research communications 20110401
Title: Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Journal: Molecular cancer therapeutics 20110401
Title: [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Journal: Bulletin du cancer 20110401
Title: Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110315
Title: First-line treatment for advanced pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011.
Journal: JOP : Journal of the pancreas 20110309
Title: Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110301
Title: Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.
Journal: American journal of physiology. Heart and circulatory physiology 20110301
Title: New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110301
Title: Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Journal: Molecular cancer therapeutics 20110301
Title: Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Journal: Cell cycle (Georgetown, Tex.) 20110301
Title: Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Journal: Cancer research 20110301
Title: Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Journal: Anticancer research 20110301
Title: A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Journal: Clinical colorectal cancer 20110301
Title: HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110220
Title: A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Journal: Archives of gynecology and obstetrics 20110201
Title: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110201
Title: The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Journal: Expert review of anticancer therapy 20110201
Title: Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
Journal: Current opinion in obstetrics & gynecology 20110201
Title: [Her2 positive breast cancer: practices].
Journal: Bulletin du cancer 20110201
Title: The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Journal: Clinical breast cancer 20110201
Title: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Journal: Cancer cell 20110118
Title: Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Journal: Cancer biology & therapy 20110115
Title: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110
Title: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Journal: Breast cancer (Tokyo, Japan) 20110101
Title: Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Journal: Journal of cellular physiology 20110101
Title: Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Journal: Cancer science 20110101
Title: High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
Journal: Breast cancer research and treatment 20110101
Title: Lapatinib for breast cancer: a review of the current literature.
Journal: Expert opinion on drug safety 20110101
Title: HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Journal: Molecular endocrinology (Baltimore, Md.) 20110101
Title: EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Journal: Frontiers in bioscience (Landmark edition) 20110101
Title: Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Journal: Breast cancer research : BCR 20110101
Title: Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Journal: Breast cancer research : BCR 20110101
Title: Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Journal: Onkologie 20110101
Title: Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
Journal: Journal of computer assisted tomography 20110101
Title: [Breast cancer therapy with combination of endocrine and target drugs].
Journal: Voprosy onkologii 20110101
Title: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Journal: BMC cancer 20110101
Title: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Journal: Breast cancer research : BCR 20110101
Title: [Targeted therapies in breast cancer].
Journal: Revue medicale de Liege 20110101
Title: β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Journal: Breast cancer research : BCR 20110101
Title: Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
Journal: PloS one 20110101
Title: Lapatinib in the treatment of HER-2 overexpressing breast cancer.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101
Title: Surrogate markers for targeted therapy-based treatment activity and efficacy.
Journal: Journal of the National Cancer Institute. Monographs 20110101
Title: Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Journal: Journal of the National Cancer Institute. Monographs 20110101
Title: Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Journal: Journal of the National Cancer Institute. Monographs 20110101
Title: Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Journal: PloS one 20110101
Title: Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Journal: Breast cancer research : BCR 20110101
Title: Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Journal: Health technology assessment (Winchester, England) 20110101
Title: Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.
Journal: PloS one 20110101
Title: [Novel target therapies used in breast cancer management].
Journal: Voprosy onkologii 20110101
Title: Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Journal: Journal of medicinal chemistry 20101223
Title: Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Journal: The Tokai journal of experimental and clinical medicine 20101220
Title: Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20101215
Title: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Journal: American journal of clinical oncology 20101201
Title: Role of anti-Her-2 therapy in bladder carcinoma.
Journal: Journal of cancer research and clinical oncology 20101201
Title: A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.
Journal: Molecular cancer therapeutics 20101201
Title: The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Journal: Anticancer research 20101201
Title: [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20101201
Title: Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.
Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20101201
Title: The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Journal: Cancer biology & therapy 20101115
Title: Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
Journal: Japanese journal of clinical oncology 20101101
Title: Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.
Journal: Current cancer drug targets 20101101
Title: Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Journal: Cancer biology & therapy 20101101
Title: Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Journal: Cancer biology & therapy 20101101
Title: Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Journal: Cancer chemotherapy and pharmacology 20101101
Title: Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Journal: Wiener medizinische Wochenschrift (1946) 20101101
Title: Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Journal: Respiratory care 20101101
Title: [Principles and method of action of targeted therapies].
Journal: Wiener medizinische Wochenschrift (1946) 20101101
Title: [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20101101
Title: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
Journal: Cancer treatment reviews 20101101
Title: Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Journal: Cancer treatment reviews 20101101
Title: Lapatinib in breast cancer: clinical experiences and future perspectives.
Journal: Cancer treatment reviews 20101101
Title: An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Journal: Investigational new drugs 20101001
Title: Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Journal: Molecular pharmacology 20101001
Title: Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001
Title: Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Journal: Cancer science 20101001
Title: [HER2 ASCO guidelines. The answer to everything?].
Journal: Der Pathologe 20101001
Title: [Therapeutic targets and molecular mechanisms].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20101001
Title: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100920
Title: Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
Journal: Breast cancer research and treatment 20100901
Title: Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Journal: Hepatology (Baltimore, Md.) 20100901
Title: Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100901
Title: Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Journal: The oncologist 20100901
Title: Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Journal: The oncologist 20100901
Title: Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Journal: Clinical breast cancer 20100901
Title: [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100901
Title: Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.
Journal: The Netherlands journal of medicine 20100901
Title: Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Journal: Cancer letters 20100828
Title: Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Journal: Investigational new drugs 20100801
Title: Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Journal: Critical reviews in oncology/hematology 20100801
Title: Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
Journal: Cancer treatment reviews 20100801
Title: Targeted therapy in breast cancer: current status and future directions.
Journal: Japanese journal of clinical oncology 20100801
Title: ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Journal: Neuro-oncology 20100801
Title: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801
Title: Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801
Title: Lapatinib and breast cancer: current indications and outlook for the future.
Journal: Expert review of anticancer therapy 20100801
Title: Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Journal: Drugs 20100730
Title: Decoupling of receptor and downstream signals in the Akt pathway by its low-pass filter characteristics.
Journal: Science signaling 20100727
Title: Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710
Title: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.
Journal: Breast cancer research and treatment 20100701
Title: Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization.
Journal: Basic & clinical pharmacology & toxicology 20100701
Title: Trastuzumab in gastric cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20100701
Title: MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Journal: Molecular cancer therapeutics 20100701
Title: Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620
Title: Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Journal: International journal of cancer 20100615
Title: NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Journal: BMJ (Clinical research ed.) 20100611
Title: Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.
Journal: Anti-cancer drugs 20100601
Title: Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Journal: Current cancer drug targets 20100601
Title: Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
Journal: International journal of radiation oncology, biology, physics 20100601
Title: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Journal: Molecular cancer therapeutics 20100601
Title: Novel targeted therapies in inflammatory breast cancer.
Journal: Cancer 20100601
Title: Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Journal: Wiener klinische Wochenschrift 20100601
Title: HER2 as a target for breast cancer therapy.
Journal: Expert opinion on biological therapy 20100501
Title: Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.
Journal: Current medical research and opinion 20100501
Title: Systemic treatment in breast-cancer patients with brain metastasis.
Journal: Expert opinion on pharmacotherapy 20100501
Title: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100501
Title: Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Journal: Molecular cancer therapeutics 20100501
Title: HER2-positive breast cancer: beyond trastuzumab.
Journal: Oncology (Williston Park, N.Y.) 20100430
Title: Targeting alternative pathways in HER2-positive breast cancer.
Journal: Oncology (Williston Park, N.Y.) 20100430
Title: Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Journal: Investigational new drugs 20100401
Title: Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Journal: Current medical research and opinion 20100401
Title: Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Journal: Oncology reports 20100401
Title: Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Journal: Clinical pharmacology and therapeutics 20100401
Title: Lapatinib side-effect management.
Journal: Clinical journal of oncology nursing 20100401
Title: Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Journal: British journal of cancer 20100316
Title: Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.
Journal: Cancer research 20100315
Title: Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100315
Title: An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100301
Title: Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20100301
Title: Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Journal: Current cancer drug targets 20100301
Title: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301
Title: [Management of metastatic HER2-positive breast cancer: present and future].
Journal: Bulletin du cancer 20100301
Title: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100301
Title: Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100301
Title: Does lapatinib work against HER2-negative breast cancers?
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100301
Title: Breast cancer drug approved for new indication.
Journal: Women's health (London, England) 20100301
Title: HER2 as a cancer stem-cell target.
Journal: The Lancet. Oncology 20100301
Title: Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
Journal: Cancer science 20100201
Title: Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
Journal: Nature reviews. Clinical oncology 20100201
Title: Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100201
Title: Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
Journal: Molecular cancer therapeutics 20100201
Title: Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Journal: Expert review of anticancer therapy 20100201
Title: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Journal: The oncologist 20100201
Title: Updates on therapeutic approaches in HER2-positive disease.
Journal: Clinical advances in hematology & oncology : H&O 20100201
Title: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Journal: Science translational medicine 20100127
Title: Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Journal: Biochemical pharmacology 20100115
Title: Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Journal: American journal of respiratory and critical care medicine 20100115
Title: A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Journal: Cancer chemotherapy and pharmacology 20100101
Title: Lapatinib.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
Title: Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Journal: PloS one 20100101
Title: Targeted HER2 treatment in advanced gastric cancer.
Journal: Oncology 20100101
Title: Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.
Journal: PloS one 20100101
Title: Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Journal: BMC cancer 20100101
Title: [Novel targeted drug therapies in breast cancer].
Journal: Duodecim; laaketieteellinen aikakauskirja 20100101
Title: Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
Journal: The breast journal 20100101
Title: Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
Journal: Breast cancer research : BCR 20100101
Title: A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Journal: Oncology 20100101
Title: The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Journal: International journal of cancer 20091215
Title: EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Journal: Science signaling 20091215
Title: Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
Journal: Oncogene 20091203
Title: Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Journal: Cancer treatment reviews 20091201
Title: Clinical pharmacokinetics of tyrosine kinase inhibitors.
Journal: Cancer treatment reviews 20091201
Title: Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201
Title: Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20091201
Title: Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201
Title: Current combination chemotherapy regimens for metastatic breast cancer.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201
Title: Small-molecule inhibitors of the human epidermal receptor family.
Journal: Expert opinion on investigational drugs 20091201
Title: [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Journal: Magyar onkologia 20091201
Title: [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20091201
Title: How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120
Title: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120
Title: Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120
Title: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Journal: British journal of cancer 20091117
Title: Lapatinib as a chemotherapeutic drug.
Journal: Recent patents on anti-cancer drug discovery 20091101
Title: Trastuzumab versus lapatinib: the cardiac side of the story.
Journal: Cancer treatment reviews 20091101
Title: Lapatinib: a competitor or companion to trastuzumab?
Journal: Cancer treatment reviews 20091101
Title: Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.
Journal: Anti-cancer drugs 20091101
Title: Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Journal: Cancer biology & therapy 20091101
Title: A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091101
Title: Lapatinib in metastatic breast cancer.
Journal: Women's health (London, England) 20091101
Title: Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Journal: Neoplasia (New York, N.Y.) 20091101
Title: Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Journal: Expert review of anticancer therapy 20091101
Title: Autophagy can contribute to cell death when combining targeted therapy.
Journal: Cancer biology & therapy 20091101
Title: Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Journal: Drugs 20091022
Title: Gastric cancer: trastuzumab trial results spur search for other targets.
Journal: Journal of the National Cancer Institute 20091007
Title: Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
Journal: Breast cancer research and treatment 20091001
Title: Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Journal: Pediatric blood & cancer 20091001
Title: Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Journal: Oral oncology 20091001
Title: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Journal: Nature genetics 20091001
Title: Lapatinib for the treatment of HER2-overexpressing breast cancer.
Journal: Health technology assessment (Winchester, England) 20091001
Title: Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
Journal: Oncology (Williston Park, N.Y.) 20091001
Title: Targeting breast cancer stem cells.
Journal: Breast (Edinburgh, Scotland) 20091001
Title: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090915
Title: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Journal: Cancer chemotherapy and pharmacology 20090901
Title: Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20090901
Title: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Journal: Cancer research 20090901
Title: A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090901
Title: Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Journal: Sao Paulo medical journal = Revista paulista de medicina 20090901
Title: Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090820
Title: [Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].
Journal: Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090810
Title: Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Journal: Head & neck 20090801
Title: Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Journal: Head & neck 20090801
Title: Effects of food on bioavailability of lapatinib: useful data, wrong conclusion.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801
Title: Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.
Journal: Cancer research 20090801
Title: Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Journal: Molecular cancer therapeutics 20090801
Title: In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
Journal: Biochemistry 20090721
Title: Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715
Title: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Journal: Cancer 20090701
Title: FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Journal: International journal of oncology 20090701
Title: mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090701
Title: Treatment of brain metastases in patients with HER2+ breast cancer.
Journal: Advances in therapy 20090701
Title: Information for patients. HER2: what you need to know.
Journal: Oncology (Williston Park, N.Y.) 20090701
Title: Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Journal: The Journal of biological chemistry 20090619
Title: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20090601
Title: Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Journal: The Lancet. Oncology 20090601
Title: ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090601
Title: Lapatinib for inflammatory breast cancer.
Journal: The Lancet. Oncology 20090601
Title: Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
Journal: Nature reviews. Clinical oncology 20090601
Title: Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Journal: Biochemical pharmacology 20090515
Title: Dual targeting of EGFR and HER-2 in colon cancer cell lines.
Journal: Cancer chemotherapy and pharmacology 20090501
Title: No cure in sight for the world's drug problem.
Journal: The Lancet. Oncology 20090501
Title: Medicinal chemistry strategies in follow-on drug discovery.
Journal: Drug discovery today 20090501
Title: Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410
Title: Treatment of metastatic breast cancer: looking towards the future.
Journal: Breast cancer research and treatment 20090401
Title: Analysis of dermatologic events in patients with cancer treated with lapatinib.
Journal: Breast cancer research and treatment 20090401
Title: Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.
Journal: Journal of cancer research and clinical oncology 20090401
Title: Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Journal: International journal of oncology 20090401
Title: Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Journal: Journal of the National Cancer Institute 20090401
Title: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Journal: The oncologist 20090401
Title: Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.
Journal: British journal of clinical pharmacology 20090401
Title: Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Journal: Targeted oncology 20090401
Title: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090315
Title: microRNA-205 regulates HER3 in human breast cancer.
Journal: Cancer research 20090315
Title: Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Journal: Dermatology online journal 20090315
Title: Effects of food on the relative bioavailability of lapatinib in cancer patients.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310
Title: Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301
Title: [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Journal: Magyar onkologia 20090301
Title: Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Journal: Drug news & perspectives 20090301
Title: An overview of HER-targeted therapy with lapatinib in breast cancer.
Journal: Advances in therapy 20090301
Title: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090215
Title: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Journal: Oncogene 20090212
Title: Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
Journal: Japanese journal of clinical oncology 20090201
Title: An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090201
Title: Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20090201
Title: Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Journal: Cancer 20090201
Title: Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Journal: Journal of the National Cancer Institute 20090121
Title: How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110
Title: Ten years of HER2-directed therapy: still questions after all these years.
Journal: Breast cancer research and treatment 20090101
Title: New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Journal: Nature clinical practice. Oncology 20090101
Title: Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
Journal: Seminars in radiation oncology 20090101
Title: Acute paronychia caused by lapatinib therapy.
Journal: Clinical and experimental dermatology 20090101
Title: Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.
Journal: Critical care medicine 20090101
Title: San Antonio Breast Cancer Symposium.
Journal: The Lancet. Oncology 20090101
Title: Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
Journal: American journal of therapeutics 20090101
Title: The 'win-win' initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Journal: World journal of surgical oncology 20090101
Title: Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.
Journal: JPEN. Journal of parenteral and enteral nutrition 20090101
Title: Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.
Journal: PloS one 20090101
Title: Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Journal: PloS one 20090101
Title: Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Journal: Cancer treatment and research 20090101
Title: Costs of adjuvant breast cancer treatments.
Journal: Cancer treatment and research 20090101
Title: Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Journal: Breast cancer research : BCR 20090101
Title: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Journal: Clinical therapeutics 20090101
Title: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Journal: Cancer letters 20081218
Title: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Journal: Breast cancer research and treatment 20081201
Title: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201
Title: Jumping higher: is it still possible? The ALTTO trial challenge.
Journal: Expert review of anticancer therapy 20081201
Title: HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081201
Title: Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081201
Title: Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.
Journal: Cancer research 20081201
Title: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Journal: Cancer research 20081115
Title: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Journal: Breast cancer research and treatment 20081101
Title: Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
Journal: Clinical and experimental dermatology 20081101
Title: Are volumetric changes of brain metastases the best evaluation of efficacy?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081101
Title: Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081101
Title: [Stem cell-targeted therapy--a new strategy for cancer treatment].
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] 20081101
Title: Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Journal: The Biochemical journal 20081015
Title: [Targeted therapy for metastatic bladder cancer].
Journal: Der Urologe. Ausg. A 20081001
Title: A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Journal: Gynecologic oncology 20081001
Title: EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Journal: Expert opinion on investigational drugs 20081001
Title: Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Journal: Pharmacotherapy 20081001
Title: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Journal: Cancer research 20081001
Title: Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Journal: Health technology assessment (Winchester, England) 20081001
Title: FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Journal: The oncologist 20081001
Title: Unraveling the biologic and clinical complexities of HER2.
Journal: Clinical breast cancer 20081001
Title: Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Journal: Clinical breast cancer 20081001
Title: Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080915
Title: Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Journal: European journal of pharmacology 20080904
Title: Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Journal: British journal of cancer 20080902
Title: Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Journal: Molecular pharmacology 20080901
Title: Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Journal: Nature clinical practice. Oncology 20080901
Title: [Novel targeting therapy concept for breast cancer treatment].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080901
Title: As metastasis yields its biological secrets, researchers hope to apply findings.
Journal: Journal of the National Cancer Institute 20080806
Title: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Journal: Journal of the National Cancer Institute 20080806
Title: Drug development in the targeted therapy era.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801
Title: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Journal: Clinical therapeutics 20080801
Title: A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080715
Title: Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710
Title: Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710
Title: Focus on ERBB2.
Journal: Pharmacogenomics 20080701
Title: Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Journal: Molecular cancer therapeutics 20080701
Title: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620
Title: Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620
Title: Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620
Title: Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Journal: The Prostate 20080615
Title: A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080601
Title: Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080601
Title: Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain)) 20080601
Title: [Oncology 2008].
Journal: Deutsche medizinische Wochenschrift (1946) 20080601
Title: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
Journal: Mayo Clinic proceedings 20080601
Title: Molecularly targeted therapy in breast cancer: the new generation.
Journal: Recent patents on anti-cancer drug discovery 20080601
Title: Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Journal: Journal of the National Cancer Institute 20080521
Title: Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510
Title: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Journal: Journal of the National Cancer Institute 20080507
Title: Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
Journal: Breast cancer research and treatment 20080501
Title: [Combined chemotherapy with molecular-targeted agent for breast cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20080501
Title: [Advances in research on treatment of breast cancer with lapatinib].
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080501
Title: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420
Title: EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080415
Title: Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080401
Title: The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080401
Title: Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Journal: American journal of clinical oncology 20080401
Title: Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Journal: Seminars in oncology 20080401
Title: Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Journal: Molecular cancer therapeutics 20080401
Title: Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Journal: Clinical breast cancer 20080401
Title: [New treatment approaches in breast cancer].
Journal: Therapeutische Umschau. Revue therapeutique 20080401
Title: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Journal: British journal of cancer 20080325
Title: Treatment of breast cancer with trastuzumab during pregnancy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320
Title: Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Journal: Bioorganic & medicinal chemistry letters 20080315
Title: Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts.
Journal: Annals of the rheumatic diseases 20080301
Title: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301
Title: Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Journal: Structure (London, England : 1993) 20080301
Title: Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Journal: Molecular cancer therapeutics 20080301
Title: Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Journal: Expert review of anticancer therapy 20080301
Title: [The new generation of breast cancer clinical trials: the right drug for the right target].
Journal: Bulletin du cancer 20080301
Title: Lapatinib: a sword with two edges.
Journal: Pathology oncology research : POR 20080301
Title: Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Journal: Clinical breast cancer 20080301
Title: Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Journal: Clinical breast cancer 20080301
Title: Advances in HER2-positive breast cancer.
Journal: Clinical advances in hematology & oncology : H&O 20080201
Title: Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Journal: Clinical breast cancer 20080201
Title: [Metastatic breast cancer--new methods of treatment].
Journal: MMW Fortschritte der Medizin 20080117
Title: Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Journal: Cancer research 20080115
Title: SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Journal: Anti-cancer drugs 20080101
Title: Development of new targeted therapies for breast cancer.
Journal: Breast cancer (Tokyo, Japan) 20080101
Title: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Journal: Current medicinal chemistry 20080101
Title: Cell signaling modifiers in prostate cancer.
Journal: Cancer journal (Sudbury, Mass.) 20080101
Title: The emerging role of lapatinib in HER2-positive breast cancer.
Journal: Current oncology reports 20080101
Title: Promising newer molecular-targeted therapies in head and neck cancer.
Journal: Drugs 20080101
Title: Targeting Her-2/neu in breast cancer: as easy as this!
Journal: Oncology 20080101
Title: EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Journal: TheScientificWorldJournal 20080101
Title: tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Journal: BMC cancer 20080101
Title: A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20071201
Title: Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.
Journal: Journal of the Egyptian National Cancer Institute 20071201
Title: The value of label recommendations: how to dose lapatinib.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120
Title: Effect of food on lapatinib pharmacokinetics.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120
Title: The value meal: effect of food on lapatinib bioavailability.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120
Title: Controversies in using lapatinib at reduced dosage with food.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120
Title: Overcoming treatment challenges in advanced breast cancer.
Journal: Seminars in oncology nursing 20071101
Title: Choosing the appropriate breast cancer therapy for today's breast cancer patient.
Journal: Seminars in oncology nursing 20071101
Title: Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Journal: Oncology (Williston Park, N.Y.) 20071001
Title: FDA approves new drug for specific type of advanced breast cancer.
Journal: Mayo Clinic women's healthsource 20071001
Title: Lapatinib (Tykerb) for advanced breast cancer.
Journal: The Medical letter on drugs and therapeutics 20070910
Title: [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Journal: Ugeskrift for laeger 20070910
Title: Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.
Journal: Expert opinion on pharmacotherapy 20070901
Title: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901
Title: A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
Journal: Mayo Clinic proceedings 20070901
Title: Dissecting kinase signaling pathways.
Journal: Drug discovery today 20070901
Title: Lapatinib in the treatment of breast cancer.
Journal: Expert review of anticancer therapy 20070901
Title: HER2 targeted therapy in breast cancer...beyond Herceptin.
Journal: Reviews in endocrine & metabolic disorders 20070901
Title: Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901
Title: Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070820
Title: The value meal: how to save $1,700 per month or more on lapatinib.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810
Title: Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
Journal: Cell proliferation 20070801
Title: Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070801
Title: Food effects on oral agents.
Journal: Clinical advances in hematology & oncology : H&O 20070801
Title: Lapatinib-associated toxicity and practical management recommendations.
Journal: The oncologist 20070701
Title: [Breast cancer and Her-2].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20070628
Title: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070601
Title: Her signaling in pancreatic cancer.
Journal: Expert opinion on biological therapy 20070601
Title: Lapatinib in breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070601
Title: Lapatinib.
Journal: Nature reviews. Drug discovery 20070601
Title: Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Journal: Clinical advances in hematology & oncology : H&O 20070601
Title: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Journal: Nature reviews. Cancer 20070501
Title: Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
Journal: Molecular cancer therapeutics 20070501
Title: Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.
Journal: Reviews on recent clinical trials 20070501
Title: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Journal: Journal of the National Cancer Institute 20070418
Title: Lapatinib plus capecitabine in breast cancer.
Journal: The New England journal of medicine 20070405
Title: Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Journal: Journal of the National Cancer Institute 20070307
Title: The EGF receptor Hokey-Cokey.
Journal: Cancer cell 20070301
Title: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Journal: Cancer cell 20070301
Title: Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20070301
Title: Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Journal: Oncology reports 20070201
Title: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.
Journal: Expert opinion on biological therapy 20070201
Title: Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Journal: Cancer research 20070201
Title: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Journal: Molecular cancer therapeutics 20070201
Title: Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Journal: Urology 20070201
Title: TEACH: Tykerb evaluation after chemotherapy.
Journal: Clinical breast cancer 20070201
Title: Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Journal: Japanese journal of clinical oncology 20070101
Title: HER-2-positive breast cancer: hope beyond trastuzumab.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20070101
Title: relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.
Journal: Theoretical biology & medical modelling 20070101
Title: Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Journal: Breast cancer (Tokyo, Japan) 20070101
Title: New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.
Journal: Journal of the American Pharmacists Association : JAPhA 20070101
Title: Pharmacology of epidermal growth factor inhibitors.
Journal: The International journal of biological markers 20070101
Title: Rationale and clinical results of multi-target treatments in oncology.
Journal: The International journal of biological markers 20070101
Title: Molecular targeted therapies in breast cancer: where are we now?
Journal: The international journal of biochemistry & cell biology 20070101
Title: HER2-positive breast cancer: current and future treatment strategies.
Journal: Drugs 20070101
Title: EGFR and HER-2 antagonists in breast cancer.
Journal: Anticancer research 20070101
Title: Lapatinib shows promise for inflammatory breast cancer.
Journal: Cancer biology & therapy 20070101
Title: Targeting the epidermal growth factor receptor in colorectal carcinoma.
Journal: Cancer nursing 20070101
Title: Targeted therapies in breast cancer: challenging questions from oncology nurses.
Journal: ONS connect 20070101
Title: Lapatinib.
Journal: Drugs 20070101
Title: Why are promising new drugs for dying patients still out of reach?
Journal: MedGenMed : Medscape general medicine 20070101
Title: [Targeting ErbB receptors in breast cancer].
Journal: Bulletin du cancer 20070101
Title: Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Journal: The New England journal of medicine 20061228
Title: Targeted therapy for metastatic breast cancer.
Journal: The New England journal of medicine 20061228
Title: Closing in on a cure.
Journal: U.S. news & world report 20061023
Title: Delivery of a healthy baby after first-trimester maternal exposure to lapatinib.
Journal: Clinical breast cancer 20061001
Title: Three new drugs available to fight kidney cancer.
Journal: Journal of the National Cancer Institute 20060906
Title: Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Journal: Bioorganic & medicinal chemistry letters 20060901
Title: Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
Journal: Anti-cancer drugs 20060901
Title: Two targets, one drug for new EGFR inhibitors.
Journal: Journal of the National Cancer Institute 20060816
Title: New hope for RCC patients.
Journal: European journal of cancer (Oxford, England : 1990) 20060801
Title: Trials probe new agents for kidney cancer.
Journal: JAMA 20060712
Title: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.
Journal: Drugs of today (Barcelona, Spain : 1998) 20060701
Title: Systemic therapy in the palliative management of advanced salivary gland cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060610
Title: [Molecular-targeted agents in breast cancer].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20060601
Title: Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Journal: Current oncology reports 20060301
Title: Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202
Title: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Journal: The Annals of pharmacotherapy 20060201
Title: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Journal: Cancer research 20060201
Title: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Journal: Cancer research 20060201
Title: Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Journal: Cancer research 20060101
Title: Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Journal: Current topics in medicinal chemistry 20060101
Title: Lapatinib: current status and future directions in breast cancer.
Journal: The oncologist 20060101
Title: Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.
Journal: Advances in experimental medicine and biology 20060101
Title: GlaxoSmithKline cancer drug threatens Herceptin market.
Journal: Nature biotechnology 20051201
Title: Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Journal: Clinical breast cancer 20051201
Title: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Journal: Oncogene 20050915
Title: Antitumor activity of HER-2 inhibitors.
Journal: Cancer letters 20050908
Title: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810
Title: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Journal: Cancer research 20050415
Title: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410
Title: The epidermal growth factor receptor as a target for colorectal cancer therapy.
Journal: Seminars in oncology 20050201
Title: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
Journal: Investigational new drugs 20050101
Title: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Journal: Cancer research 20050101
Title: Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Journal: Oncology 20050101
Title: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Journal: Cancer research 20040915
Title: Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
Journal: Cancer biology & therapy 20040601
Title: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Journal: International journal of radiation oncology, biology, physics 20040201
Title: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Journal: Oncogene 20040122
Title: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
Journal: The oncologist 20040101
Title: Targeting HER2 in brain metastases from breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031115
Title: Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands) 20030801
Title: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Journal: Oncogene 20020912
